Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/207749
Title: | Pregnancy outcomes in antiphospholipid antibody positive patients: prospective results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ('Registry'). |
Author: | Erton, Zeynep Belce Sevim, Ecem de Jesús, Guilherme Ramires Cervera i Segura, Ricard, 1960- Ji, Lan Lan Pengo, Vittorio Ugarte, Amaia Andrade, Danieli Andreoli, Laura Atsumi, Tatsuya Fortin, Paul R. Gerosa, Maria Zuo, Yu Petri, Michelle Sciascia, Savino Tektonidou, Maria Aguirre Zamorano, Mª. Ángeles Branch, D Ware Erkan, Doruk |
Keywords: | Embaràs Mort del fetus Avortament Lupus eritematós Síndrome antifosfolipídica Assaigs clínics Pregnancy Fetal death Abortion Lupus erythematosus Antiphospholipid syndrome Clinical trials |
Issue Date: | 14-Jun-2022 |
Publisher: | BMJ Publishing Group |
Abstract: | Objectives: To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since the inception of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods: We identified persistently aPL-positive patients recorded as 'pregnant' during prospective follow-up, and defined 'aPL-related outcome' as a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or placental insufficiency (PI); or (2) Otherwise unexplained fetal death after the 10th week of gestation. The primary objective was to describe the characteristics of patients with and without aPL-related composite outcomes based on their first observed pregnancies following registry recruitment. Results: Of the 55 first pregnancies observed after registry recruitment among nulliparous and multiparous participants, 15 (27%) resulted in early pregnancy loss <10 weeks gestation. Of the remaining 40 pregnancies: (1) 26 (65%) resulted in term live delivery (TLD), 4 (10%) in PTLD between 34.0 weeks and 36.6 weeks, 5 (12.5%) in PTLD before 34th week, and 5 (12.5%) in fetal death (two associated with genetic anomalies); and (2) The aPL-related composite outcome occurred in 9 (23%). One of 26 (4%) pregnancies with TLD, 3/4 (75%) with PTLD between 34.0 weeks and 36.6 weeks, and 3/5 (60%) with PTLD before 34th week were complicated with PEC, SGA and/or PI. Fifty of 55 (91%) pregnancies were in lupus anticoagulant positive subjects, as well as all pregnancies with aPL-related composite outcome. Conclusion: In our multicentre, international, aPL-positive cohort, of 55 first pregnancies observed prospectively, 15 (27%) were complicated by early pregnancy loss. Of the remaining 40 pregnancies, composite pregnancy morbidity was observed in 9 (23%) pregnancies. |
Note: | Reproducció del document publicat a: https://doi.org/10.1136/lupus-2021-000633 |
It is part of: | Lupus Science & Medicine, 2022, vol. 9, num.1, e000633 |
URI: | http://hdl.handle.net/2445/207749 |
Related resource: | https://doi.org/10.1136/lupus-2021-000633 |
ISSN: | 2053-8790 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
258010.pdf | 683.82 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License